COPD

Inhaled anticholinergic bronchodilator tiotropium as an add-on therapy has the potential to reduce exacerbations.

The first once-daily, triple-therapy inhaler drug was originally approved by the FDA in September.

The biologic agent has shown efficacy in reducing asthma exacerbations and improving patient quality of life.

There's a perfect storm brewing that makes telemedicine an inevitability in the management of conditions like asthma and COPD.

After implementing a team-based care approach to COPD, one hospital saved $600 per patient, per year.

Stay updated on the biggest headlines with MDNN from October 20, 2017.

As COPD exacerbations continue to plague patients, the AIRWISE trial will examine LAMA/LABA/ICS combinations.

The FDA approved the inhaler treatment based on 2 Phase III-B studies running 6 months and 12 months, respectively, to compare the drug’s efficacy in COPD exacerbation care.

COPD-related deaths increased 11.6% since 1990, and cases increased 44.2% to 174.5 million.

The FDA accepted an abbreviated new drug application for Sandoz ANDA.

Meredith McCormack, MD, MHS, talked about managing asthma and COPD in the primary care setting and when it’s time to refer a patient to a specialist at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

A new study from Georgia State University examined the mechanisms by which resveratrol was able to work against Haemophilus influenzae, a major respiratory pathogen. The findings may be of use in developing non-antibiotic treatments for bacterial respiratory infections, and also for COPD and asthma therapies.

For patients who struggle with positive airway pressure machines there have been developments in recent years to help them treat their sleep apnea and other disorders.

Whether it is obstructive or central sleep apnea or any number of other conditions finding the right treatment method can make a big difference in improving quality of life.